VISEN Pharmaceuticals executed a further share buyback on 8 June 2026, repurchasing 5,700 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HKD 20.40 to HKD 20.74. The transaction cost totalled HKD 0.12 million.

Following the trade, the company’s issued share capital (excluding treasury shares) declined by 0.005 % to 113.83 million shares, while treasury shares increased to 97,400. The total share count, including treasury shares, remained unchanged at 113.93 million.

The latest purchase brings cumulative buybacks under the mandate approved on 27 June 2025 to 97,400 shares, equivalent to 0.09 % of the shares outstanding on the mandate date. VISEN Pharma is authorised to repurchase up to 11.39 million shares under the existing mandate and is subject to a 30-day moratorium—lasting until 8 July 2026—on issuing new shares or selling treasury shares following this repurchase.